Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.

You may also be interested in...



Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA

A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path

Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA

A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path

Debiovision’s Sanvar Will Be Tough Sell To Advisory Panel

FDA has declared any positive results from a study of vapreotide to be statistically insignificant, immeasurably biased and possibly due to the endoscopic therapy rather than the drug.

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel